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Oral Presentations S159Relapse rates in patients (pts) after autologous stem cell transplant
(SCT) for high risk or refractoryNHL remains high. Our preclinical
studies showed that activated T cells (ATC) armed with anti-CD3 x
anti-CD20 bispecific antibody (CD20Bi) lyse rituximab-resistant
CD201 lymphoma cells. A phase I trial was conducted in 15 high
risk or refractory NHL pts to determine the safety of armed ATC
(aATC) given after SCT and whether aATC infusions accelerate im-
mune recovery and provide an anti-lymphoma effect. Leukopheresis
products were activated with anti-CD3, expanded in IL-2, armed
with CD20Bi, and cryopreserved for infusions after SCT. At the
time of SCT, there were 6 pts in 1st or 2nd remission (CR), 4 pts
had refractory disease (PRD), 4 pts were in partial response, and 1
pt had progressive disease (PD). Pts received 5-20  109 aATC
per infusion. The first 3 patients received 5x109 three times per
week for 3 weeks and then once per week for 6 weeks for a total
aATC dose of 75x109. Subsequently, the schedule was revised to 1
infusion/week for 4 weeks with infusion doses of 10, 15, and
20x109 aATC. The median dose of CD341 cells/kg infused was
4.0x106(1.04-12.3x106). The ATC product was 92% viable, con-
tainedmedians of 96.5%CD3, 67%CD4, and 48.9%CD8 cells. Fif-
teen pts received aATC and 12 were evaluable for toxicities. The
Table 1 summarizes grade 1-3 events.
Table 1. Grade-1-3 Events
Dose 5 billion 10 billion 15 billion 20 billionPts Number 3 3 3 3
Infusions 15 4 4 4
Fever 3 10 12 12
Chills 2 7 3 4
Malaise 1 2 7 11
Hypotension 3 4 1 5
Tachycardia 3 2 5 4
Nause/vomiting 0 7 3 4
Headache 0 2 2 2
Dyspnea 1 0 0 0
Hypoxia 0 0 0 1(NCI Immunotherapy Criteria).
The median day to engraftment was 14.75 days without G-CSF.
aATC could be detected by flow cytometry up to 12 hours after in-
fusion. The proportions of CD4 cells were in the normal range up to
a month. There was a . 4x increase in the mean (6SD) number of
IFNg EliSpots in response to Daudi cells from 30.5620.5/106
PBL preSCT to 125.66130/106PBL post SCT, p\0.008. The me-
dian cytotoxicity mediated by NK cells ranged from 8.2-13.7% be-
tween 2 weeks and 3 months after SCT. Serum cytokines and
chemokines peaked around 4 hrs after aATC infusions with 1-2
log increases in IL-2, IL-7, IL-15, IL-2r, MIP-1b, IP10, MIP-1a,
MIG, and MICP-10. At 90 days after SCT, 9 pts were in CR and
6 pts had PD. The median OS has not been reached and OS is pro-
jected to be 55% at 4 years. Pts in CR prior to SCT had longer sur-
vival at 85% with no relapses after 1 year after SCT. These findings
show that: 1) ATC can be expanded from heavily pretreated NHL
pts; 2) aATC infusions are safe; 3) induce high levels of serum cyto-
kines and chemokines; and 4) may provide anti-tumor help and cyto-
toxicity after SCT.24
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Prognosis for pts with AML/MDS relapsing after allo-SCT is
poor and therapeutic options are limited. Results from recent retro-
spective analyses on the use of Aza1/- DLI in pts with AML/MDS,
who relapsed after allo-SCT, were encouraging.
To evaluate the potential of Aza combined with DLI as 1st sal-
vage therapy in pts with AML/MDS relapsing after allo-SCT we
conducted a prospective phase-II multicenter trial. Pts were al-
lowed to receive up to 8 cycles Aza (100 mg/m2/d d1-5, every 28
d) and 3 DLI with increasing dosages (1-5x106–1-5x108 cells/kg)
after every 2nd Aza cycle. So far, 25 pts (15 f/10 m) are evaluable
for this analysis.
At diagnosis 23 (92%) had AML (15 de novo/8 followingMDS), 1
(4%) MDS (RAEB-1) and 1 (4%) MDS/MPS (CMML-1). Based on
cytogenetics 21 pts belonged to an adverse or intermediate risk
group, whereas 2 pts had favorable cytogenetics (2 n.p.).
At transplant, 6 pts (24%) had induction failure, 6 (24%) suffered
from 1st or 2nd relapse, 10 pts (40%) were in 1st or 2ndCR, while 3 pts
(12%) were untreated. Eight pts (35%) received grafts from MSD
and 15 (65%) from MUD (2 pts missing data). PBSC were used in
24 pts (96%; 1 missing). Prior to relapse 9 (36%) and 3 (12%) pts
had episodes of aGvHD and/or cGvHD, respectively.
At relapse, 4 (31%) of 13 evaluable pts had normal cytogenetics,
while 9 (69%) had chromosomal aberrations including 6 pts (46%)
with complex karyotype. Relapse occurred in median 160 d (range
19-1199) after allo-SCT (BM blasts 34%, range 5-100%, donor
chimerism 63% range 1-100%). Median age was 54 y (range 29-
71). Patients received a median of 3 cycles Aza (range 1-8) and 18
pts (72%) received DLI (median: 1, range 1-4, median CD3 dose
5x106/kg/DLI, range 1-207x106).
Overall response rate was 64% with 5 pts (20%) achieving CR/
CRi, 3 (12%) PR and 8 (32%) SD. Median response duration was
266 d. Acute GvHD occurred in 6 pts (24%) (2 skin/6 liver/ 2 gut)
after a median of 65 d (range 19-179) following the 1st DLI. Three
pts (12%) had limited cGvHD. Hematotoxicity IIIo-IVo was
observed in 64%. Common adverse events were gastrointestinal
side effects and infections. After a median follow-up of 100 d (range
25-485) 15 pts (60%) are alive. Median OS of all pts is 184 d (range
87-281). All pts, who achieved a CR/CRi, remained in ongoing
remission for a median of 229 d.
Our data suggest that salvage therapy with Aza1DLI for pts with
AML/MDS relapsing after allo-SCT is feasible and has significant
anti-leukemic activity in these pts.GRAFT PROCESSING25
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Up to 30% of patients fail to collect minimum numbers of PBSC
for ASCT, and up to 50% of patients fail to collect the optimal num-
ber. Plerixafor, a CXCR4 antagonist, in combination with G-CSF
has shown superior results inmobilizing PBCD341 cells in compar-
ison to G-CSF alone for autologous PBSC mobilization in patients
with NHL or MM. However, due to its high cost, we commenced
a risk adapted algorithm for the utilization of plerixafor starting in
Feb 2009.
Jan-Dec 2008 was the baseline. Patients in upfront mobilization
clinical trials with plerixafor were excluded. From Feb-Nov 2009,
the risk adapted algorithmPlerixafor-1was used. PBSCmobilization
was commenced with G-CSF at 10 mcg/kg/day. If PB CD34 on day
4 or day 5 was$ 10/mL, apheresis was commenced the next morning.
